Wide Ranks

IMTX

Immatics N.V.

7.91

Top Statistics
Market Cap 961 M Forward PE -6.28 Revenue Growth -16.10 %
Current Ratio 3.74 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -104.01 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -6.99 Enterprise / Revenue 9.39 Price To Sales Trailing12 Months 13.57
Profitability
Profit Margins -104.01 % Operating Margins -141.64 %
Balance Sheet
Total Cash 158 M Total Cash Per Share 1.53 Total Debt 17 M
Total Debt To Equity 4.49 Current Ratio 3.74 Book Value Per Share 2.66
All Measures
Short Ratio 876.00 % Message Board Id finmb_8986547 Fax 49 7071 5397 900
Shares Short Prior Month 9 M Return On Equity -0.2432 City Tübingen
Uuid 962d0ef0-fe1e-3809-bf51-f3186685ad4f Previous Close 7.80 First Trade Date Epoch Utc 1 B
Book Value 2.66 Beta 0.7760 Total Debt 17 M
Volume 425137 Price To Book 2.97 Fifty Two Week Low 7.46
Total Cash Per Share 1.53 Total Revenue 70 M Shares Short Previous Month Date 1 B
Target Median Price 17.00 Max Age 86400 Recommendation Mean 1.29
Sand P52 Week Change 0.3133 Operating Margins -141.64 % Target Mean Price 16.75
Net Income To Common -73713000 Short Percent Of Float 0.0684 Implied Shares Outstanding 121 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 790590
Average Volume10days 790590 Total Cash 158 M Next Fiscal Year End 1 B
Revenue Per Share 0.7660 Held Percent Insiders 0.2217 Ebitda Margins -134.32 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 7.80 Target Low Price 13.50 Gmt Off Set Milliseconds -18000000
Fifty Day Average 9.63 Open 7.80 Free Cashflow -423208000
Dividend Yield 0.00 % Return On Assets -0.1217 Time Zone Short Name EST
Trailing Eps -0.6400 Day Low 7.64 Address1 Paul-Ehrlich-Strasse 15
Shares Outstanding 121 M Price Hint 2 Target High Price 20.00
Website https://www.immatics.com 52 Week Change -0.1052 Average Volume 606232
Forward Eps -1.32 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 108.20 % Is_sp_500 False Regular Market Day High 7.94
Profit Margins -104.01 % Debt To Equity 4.49 Fifty Two Week High 13.77
Day High 7.94 Shares Short 6 M Regular Market Open 7.80
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 9.39
Revenue Growth -16.10 % Shares Percent Shares Out 0.0561 Operating Cashflow -17274000
Currency USD Time Zone Full Name America/New_York Market Cap 961 M
Is_nasdaq_100 False Zip 72076 Quote Type EQUITY
Industry Biotechnology Long Name Immatics N.V. Regular Market Day Low 7.64
Held Percent Institutions 0.6873 Current Price 7.91 Enterprise To Ebitda -6.99
Financial Currency EUR Current Ratio 3.74 Gross Margins -87.72 %
Industry Disp Biotechnology Number Of Analyst Opinions 6 Country Germany
Float Shares 62 M Two Hundred Day Average 11.12 Enterprise Value 665 M
Price To Sales Trailing12 Months 13.57 Forward PE -6.28 Regular Market Volume 425137
Ebitda -95191000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Immatics N.

V.

, a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.

The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage.

The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial.

The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications.

Immatics N.

V.

is headquartered in Tübingen, Germany.